Proofpoint to Present at Upcoming Conferences
Aug 31, 2016 12:00 pm UTC| Business
SUNNYVALE, Calif., Aug. 31, 2016 -- Proofpoint, Inc. (NASDAQ:PFPT), a leading next-generation cybersecurity company, today announced its scheduled participation at the following upcoming conferences: Gary Steele,...
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Aug 31, 2016 12:00 pm UTC| Business
NORCROSS, Ga., Aug. 31, 2016 -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the...
Points and Hawaiian Airlines Introduce Global Hotel Booking Redemption Program
Aug 31, 2016 12:00 pm UTC| Business
TORONTO, Aug. 31, 2016 -- Points (TSX:PTS) (Nasdaq:PCOM), the global leader in powering loyalty commerce, and Hawaiian Airlines, Hawaii's largest and longest-serving airline, today announced the launch of a brand new...
Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences
Aug 31, 2016 12:00 pm UTC| Business
BOTHELL, Wash., Aug. 31, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business...
InterCloud Systems to Apply for Listing on OTC-QX
Aug 31, 2016 11:45 am UTC| Business
SHREWSBURY, N.J., Aug. 31, 2016 -- InterCloud Systems, Inc. (the “Company”) (NASDAQ:ICLD), a leading provider of cloud networking orchestration and automation solutions and services, today announced that rather than...
Ship Finance International Limited (NYSE: SFL) - Earnings Release
Aug 31, 2016 11:33 am UTC| Business
Hamilton, Bermuda, Aug. 31, 2016 -- Ship Finance International Limited ("Ship Finance" or the "Company") today announced its preliminary financial results for the quarter ended June 30, 2016. Highlights Declaration...
Aug 31, 2016 11:30 am UTC| Business
NEW YORK, Aug. 31, 2016 -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that data from a Phase 1b open label study of TG-1101 (ublituximab) in acute relapses of neuromyelitis optica spectrum disorder (NMOSD),...